Ibudilast

I’ll be honest — when I first came across ibudilast, I almost dismissed it. Another obscure research compound with a name that sounds like it belongs on a chemistry exam? Hard pass.

Then I read the data. A drug with a 30-year track record in Japan. Over 3.2 million patients treated. A trial published in the New England Journal of Medicine showing it slowed brain shrinkage by nearly half. And a mechanism of action that reads like a wish list for anyone serious about long-term brain health.

That got my attention. Fast.

If you’re interested in neuroprotection — not just the next trendy supplement, but a compound with real clinical muscle behind it — ibudilast deserves a spot on your radar.

The Short Version: Ibudilast (brand name Ketas, research code MN-166) is a multi-target anti-inflammatory drug approved in Japan since 1989 for asthma and post-stroke complications. It works by inhibiting PDE4, antagonizing TLR4, suppressing neuroinflammation, and boosting neurotrophic factors like NGF and GDNF. It’s one of the most evidence-backed neuroprotective compounds available — but it’s a prescription drug, not a supplement, and direct evidence for cognitive enhancement in healthy people is still lacking.

What Is Ibudilast?

Ibudilast is a small-molecule drug originally developed by Kyorin Pharmaceutical in Japan. It was approved there in 1989 — that’s over three decades of real-world clinical use. In Japan and South Korea, it’s prescribed under the brand name Ketas for bronchial asthma and cerebrovascular complications like post-stroke dizziness.

But here’s where it gets interesting for the nootropic community. Ibudilast isn’t a one-trick pony. Unlike most drugs that hit a single target, it works across multiple anti-inflammatory and neuroprotective pathways simultaneously. That multi-target profile is what caught the attention of researchers at MediciNova, who now hold the US development rights and are running clinical trials for progressive multiple sclerosis, ALS, and substance use disorders.

It’s important to set expectations here. Ibudilast is not FDA-approved in the United States or Europe. It’s a prescription medication, not a dietary supplement you can grab off the shelf. That distinction matters — both for how you think about the evidence and how you’d actually obtain it. I’ll get into sourcing later, but I want to be upfront: this is a pharmaceutical compound, and it should be treated with the respect that entails.

Reality Check: Ibudilast has serious neuroprotective evidence, but it’s not a magic focus pill. There are no studies showing it makes healthy brains work faster or sharper in the short term. Its strength is long-term brain protection — think of it as armor for your neurons, not rocket fuel.

How Does Ibudilast Work?

Here’s where ibudilast really separates itself from the pack. Most nootropics have one primary mechanism. Ibudilast has at least four that work together. Think of it like a Swiss Army knife for neuroinflammation.

The cAMP Boost. Ibudilast’s primary action is inhibiting an enzyme called phosphodiesterase 4 (PDE4), along with PDE3A, PDE10A, and PDE11. When PDE4 is blocked, your cells accumulate more cyclic AMP (cAMP) — a signaling molecule that’s central to synaptic plasticity, learning, and memory formation. Elevated cAMP activates the PKA/CREB pathway, which is essentially the molecular machinery your brain uses to strengthen neural connections and consolidate memories.

In plain English: it turns up the volume on the signaling system your brain uses to learn and adapt.

The Inflammation Shutdown. Ibudilast also antagonizes Toll-Like Receptor 4 (TLR4), a key receptor in the innate immune system. When TLR4 is overactive — as it often is in chronic stress, poor diet, or neurological conditions — it triggers a cascade of inflammation. Ibudilast puts the brakes on that cascade. It suppresses microglial activation (your brain’s resident immune cells), slashes production of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, and simultaneously boosts anti-inflammatory signals like IL-10 and IL-4.

The Neurotrophic Factor Boost. Here’s the part that genuinely excites me. Ibudilast increases the secretion of GDNF (glial-derived neurotrophic factor), NGF (nerve growth factor), and NT-4 (neurotrophin-4). These are the proteins your brain uses to grow, maintain, and repair neurons. It’s one thing to reduce damage. It’s another to actively promote repair. Ibudilast does both.

The Net Effect. You’ve got reduced inflammation, enhanced neural signaling, improved blood flow to the brain, and increased neurotrophic support — all from a single compound. That’s a rare combination, and it’s why ibudilast keeps showing up in neuroprotection research.

Pro Tip: The cAMP/CREB pathway that ibudilast activates is the same one targeted by racetams and certain adaptogens. Understanding this shared mechanism can help you build more intelligent stacks — or recognize when you’re doubling up unnecessarily.

Benefits of Ibudilast

Let me be straight about the evidence here, because honesty about what we know — and what we don’t — is what separates useful information from hype.

The Headline Result: Slowing Brain Atrophy

The strongest evidence comes from the SPRINT-MS trial, a Phase 2 randomized controlled trial published in the New England Journal of Medicine in 2018. That’s the gold standard of medical journals. In 255 patients with progressive multiple sclerosis, ibudilast slowed whole-brain atrophy by 48% compared to placebo over 96 weeks. That translates to roughly 2.5 mL less brain tissue lost.

Researchers described the result as “unprecedented.” For a progressive condition where most drugs fail entirely, a nearly 50% reduction in brain shrinkage is remarkable. The effects were especially strong in primary progressive MS.

Now, that’s a disease population, not healthy people. But here’s why it matters for everyone: brain atrophy isn’t just an MS problem. We all lose brain volume as we age. The mechanisms driving that loss — chronic neuroinflammation, oxidative stress, microglial overactivation — are the same ones ibudilast targets.

Reducing Neuroinflammation

Multiple studies confirm ibudilast’s ability to tamp down neuroinflammation. In alcohol use disorder trials, it reduced both central and peripheral inflammatory markers, including C-reactive protein and the TNF-α/IL-10 ratio. Participants showed less neural activation in response to alcohol cues and fewer heavy drinking days.

Preclinical Neuroprotection

In animal models, the results are consistently encouraging:

• Alzheimer’s disease: Improved cognitive deficits and reduced amyloid plaque and tau pathology in transgenic AD rats
• Chemotherapy-induced cognitive impairment: Prevented memory impairments from oxaliplatin in rats
• Parkinson’s disease: Attenuated neuroinflammation in the MPTP mouse model, though results here are more mixed

What’s Still Missing

I want to be clear: there are no randomized controlled trials testing ibudilast as a cognitive enhancer in healthy people. Zero. The cognitive benefits that nootropic users report are inferred from its neuroprotective and anti-inflammatory mechanisms, not from direct cognitive testing in healthy populations.

That doesn’t mean it doesn’t work for cognition. It means we don’t have the controlled data yet. The mechanistic case is strong — cAMP/CREB activation, neurotrophic support, inflammation reduction — these are all pathways directly involved in learning, memory, and mental clarity. But mechanism isn’t proof.

Insider Tip: In Japanese post-stroke studies, patients treated with ibudilast for cerebrovascular complications reported resolution of dizziness — and 6 out of 6 patients who had depression at baseline experienced significant mood improvement. That’s a small sample, but the consistency is notable.

How to Take Ibudilast

Dosing depends heavily on context — and on whether you have access to pharmaceutical-grade Ketas or a research chemical source.

The Conservative Approach (Japanese Standard)

The best-established dosing comes from decades of Japanese clinical use:

• 20 mg/day (10 mg twice daily) for asthma
• 30 mg/day (10 mg three times daily) for cerebrovascular conditions

These doses have a 30+ year safety record and an adverse event rate of just 3.39%. If you’re exploring ibudilast for general neuroprotection, this is the most sensible starting point.

The Clinical Trial Approach (Western Standard)

US-based clinical trials typically use higher doses:

• Start at 60 mg/day (divided into two doses) for the first two weeks
• Titrate up to 100 mg/day if tolerated
• Dose reductions to 60–80 mg/day are common if GI side effects emerge

Timing and Practical Details

Ibudilast has a half-life of approximately 19 hours, which means it accumulates in your system and reaches steady state over several days. This has practical implications:

• Twice-daily dosing is sufficient — you don’t need to dose three or four times a day
• Full effects likely take 1–2 weeks to manifest as the drug reaches steady-state levels
• Japanese labeling recommends taking with or after food to reduce GI discomfort
• There is no established cycling protocol — long-term continuous use is the norm in Japan with no evidence of tolerance developing

Pro Tip: Don’t expect to “feel” ibudilast the way you feel caffeine or a racetam. The effect profile is gradual and anti-inflammatory. Users typically notice improvements over weeks — less brain fog, better clarity, a sense of cognitive resilience — rather than an acute boost. Patience is part of the protocol.

A Note on Sourcing

Ibudilast is a prescription drug, not a supplement. People obtain it through:

1. Pharmaceutical-grade Ketas from Japanese pharmacies (gold standard)
2. Named Patient Import programs (e.g., Everyone.org) for legal personal import in some jurisdictions
3. Research chemical vendors — sold “for research purposes only” with no pharmaceutical-grade quality guarantee
4. Clinical trial enrollment for specific conditions

If you go the research chemical route, demand a third-party Certificate of Analysis with HPLC purity testing. And be wary of any vendor calling it a “dietary supplement” — that’s a red flag.

Side Effects and Safety

One of ibudilast’s strongest selling points is its safety profile. After 30+ years and 3.2 million patients in Japan, we have an unusually clear picture.

At Japanese Approved Doses (20–30 mg/day)

From post-marketing data covering approximately 15,000 patients:

• Overall adverse event rate: 3.39% — that’s remarkably low
• Most common: mild appetite loss (0.58%), nausea (0.56%), and minor liver enzyme elevations (0.30–0.36%)
• No pattern of serious adverse events

At Higher Western Clinical Trial Doses (50–100 mg/day)

• GI symptoms are the main issue: nausea, diarrhea, abdominal pain, vomiting
• Headache is reported at moderate frequency
• Depression was noted in some SPRINT-MS participants — this is worth monitoring
• Adverse events occurred in ~92% of ibudilast patients vs. ~88% on placebo (mostly mild)
• Serious adverse events were actually lower in the ibudilast group (16% vs. 19% placebo)

Important: If you have liver dysfunction, use caution — ibudilast is hepatically metabolized, and impaired liver function can lead to elevated plasma levels. It is not recommended during pregnancy or breastfeeding. If you’re taking anticoagulants (warfarin, aspirin, etc.), be aware of ibudilast’s anti-platelet effects and discuss with your doctor.

Drug Interactions

The good news: addiction studies showed no adverse interactions with alcohol, opioids, or methamphetamine at clinical doses. Ibudilast is metabolized by multiple CYP450 enzymes, so strong CYP inhibitors or inducers could theoretically affect levels — but specific interactions haven’t been well-characterized in the literature.

Stacking Ibudilast

Clinical stacking data for ibudilast is limited, but its mechanisms suggest some smart pairings — and a few to watch out for.

Potentially Synergistic Combinations

Lion’s Mane + Ibudilast. Both promote NGF expression through different mechanisms. Lion’s Mane’s erinacines and hericenones stimulate NGF production, while ibudilast boosts NGF, GDNF, and NT-4 through PDE inhibition and anti-inflammatory effects. The overlap is complementary, not redundant.

Omega-3 fatty acids (DHA/EPA) + Ibudilast. DHA works through resolvins and protectins — lipid mediators that actively resolve inflammation. Combined with ibudilast’s PDE4/TLR4 mechanisms, you’re hitting neuroinflammation from multiple angles.

NAC + Ibudilast. Both have been studied in substance use disorder contexts. NAC modulates glutamate and supports glutathione production, while ibudilast handles the neuroinflammatory side. Different pathways, complementary goals.

Curcumin + Ibudilast. Curcumin targets NF-κB-driven inflammation; ibudilast works through PDE4 and TLR4. Minimal mechanistic overlap, potentially additive anti-inflammatory effects.

Use Caution With

Other PDE inhibitors. Caffeine is a non-selective PDE inhibitor. Theophylline and pentoxifylline are as well. Stacking these with ibudilast could over-amplify cAMP levels, leading to headaches, GI distress, or overstimulation. If you’re a heavy coffee drinker, consider moderating intake when using ibudilast.

Blood thinners and anti-platelet agents. Ibudilast has anti-platelet activity. Combining it with aspirin, warfarin, or other anticoagulants increases bleeding risk. Talk to your doctor.

My Take

Here’s my honest assessment. Ibudilast has one of the most compelling evidence profiles I’ve seen for a neuroprotective compound. The SPRINT-MS trial alone — published in the NEJM, showing a 48% reduction in brain atrophy — puts it in rare company. Add the multi-target mechanism, the 30-year safety record, and the neurotrophic factor support, and you’ve got something genuinely special.

But — and this is a meaningful “but” — it’s not a casual recommendation.

This is a prescription pharmaceutical, not a supplement. Access is complicated. Research chemical quality varies. And there’s no direct evidence that it makes a healthy brain work better in the short term. Its value proposition is long-term protection: keeping your brain intact as you age, reducing the chronic low-grade inflammation that slowly degrades cognitive function over decades.

Who this is best for: If you’re in your 40s, 50s, or beyond and serious about neuroprotection — especially if you have a family history of neurodegeneration or have been dealing with chronic inflammation — ibudilast is worth researching with your doctor. It’s also compelling for anyone recovering from neurological injury or dealing with conditions involving neuroinflammation.

Who should look elsewhere: If you’re a healthy 25-year-old looking for a study aid, this isn’t the right tool. Start with the foundations — sleep, nutrition, exercise, stress management — and explore well-established nootropics like Bacopa Monnieri, Lion’s Mane, or creatine first.

The compound itself is impressive. The practical barriers to responsible use are real. If you can navigate the sourcing challenges and have a clinician you trust, ibudilast represents one of the most scientifically grounded options for long-term brain health on the table right now.